Quest Diagnostics Posts Year-Over-Year Growth Across Revenue, Operating Income, Net Income, and Diluted EPS on Both Reporting Windows

Bottom line

- For the three-month reporting period, Revenue from Contract with Customer, Excluding Assessed Tax was $3,043,000,000 USD and for the prior-year comparative it was $2,761,000,000 USD, with the authorized comparison indicating a year-over-year increase on a positive-to-positive basis. - For the six-month year-to-date period, Revenue from Contract with Customer, Excluding Assessed Tax was $5,938,000,000 USD compared with $5,413,000,000 USD for the prior-year comparative, also indicating a year-over-year increase on a positive-to-positive basis.

- Operating Income (Loss) for the three-month reporting period was $459,000,000 USD versus $438,000,000 USD for the prior-year comparative, with the authorized comparison indicating a year-over-year increase and a profit-to-profit transition. - Operating Income (Loss) for the six-month year-to-date period was $858,000,000 USD versus $784,000,000 USD for the prior-year comparative, again indicating a year-over-year increase and a profit-to-profit transition. - Net Income (Loss) Attributable to Parent for the three-month reporting period was $320,000,000 USD versus $282,000,000 USD for the prior-year comparative, indicating a year-over-year increase and a profit-to-profit transition.

- Net Income (Loss) Attributable to Parent for the six-month year-to-date period was $572,000,000 USD versus $502,000,000 USD for the prior-year comparative, also indicating a year-over-year increase and a profit-to-profit transition. 47 per diluted share USD/SHARES for the prior-year comparative, indicating a year-over-year increase and a profit-to-profit transition. 41 per diluted share USD/SHARES for the prior-year comparative, indicating a year-over-year increase and a profit-to-profit transition.

- The reporting entity is Quest Diagnostics Incorporated (the "Company"), identified under 0001022079, filing the form designated 10-Q for the fiscal period period-ended-2026-06-30 under accession 0001022079-26-000070 with ticker DGX, and this article covers both the three-month reporting period the three months ended June 30, 2026 and the six-month year-to-date period the six months ended June 30, 2026, each compared with its respective prior-year comparative the three months ended June 30, 2025 and the six months ended June 30, 2025.

- Source scope is the interim unaudited consolidated financial statements and the related Management's Discussion and Analysis captured under Item 2 and the controls discussion under Item 4, supported by accounting policy references including Note 2, Note 6, and Note 7, with fair-value hierarchy context drawn from the level references Level 1, Level 2, Level 3, and Level 12 and supplemental pro forma context from Note 12. - Segment-level disaggregation for the headline metrics above is not separately disclosed in the filing evidence for this filing window, and no peer or industry benchmark is provided alongside the reported figures.

- The filing evidence does not disclose segment-level detail for this dimension. - The filing evidence contains no peer or industry comparison. - The filing evidence does not attribute this change to any single cause.

- Investors comparing this window with a similarly structured profit-to-profit interim filing can cross-check the directional pattern shown here against the Lizely Finance Earnings Analysis — UFP TECHNOLOGIES INC Interim Filing: Profit-to-Profit Growth on Both Windows coverage for a like-for-like reference frame on interim year-over-year movement.

Financial performance

- Reported results frame the three-month reporting period against the prior-year three-month window and the six-month year-to-date period against its prior-year comparative, giving readers two stacked year-over-year baselines to triangulate the trajectory. - Revenue from Contract with Customer, Excluding Assessed Tax was higher than the prior period on both the three-month and six-month year-to-date windows, with the six-month reading above its prior-year comparative as well, indicating top-line expansion on each baseline.

- Operating Income (Loss) was higher than the prior period on the three-month reporting period and higher than the prior period on the six-month year-to-date period, with both periods showing a profit-to-profit transition from the prior year. - Net Income (Loss) Attributable to Parent was higher than the prior period on the three-month reporting period and higher than the prior period on the six-month year-to-date period, again with a profit-to-profit transition on each window. - Earnings Per Share, Diluted was higher than the prior period on the three-month reporting period and higher than the prior period on the six-month year-to-date period, retaining a profit-to-profit transition on both windows and signaling that per-share earnings participated in the bottom-line improvement.

- The interim unaudited consolidated financial statements reflect all adjustments that management considers necessary for a fair presentation, and except as otherwise disclosed those adjustments are of a normal recurring nature; operating results for interim periods are not necessarily indicative of results that may be expected for the full year, a standard caveat that readers should weight when extrapolating. - The accounting policies of the Company are the same as those set forth in Note 2 to the audited consolidated financial statements contained in the Company’s prior Annual Report, which means the interim figures sit on a consistent policy base rather than a restated framework.

- A newly issued FASB standard on disaggregation of certain income statement expenses is effective for the Company's annual filings for the year ended December (omitted) and for interim periods within that year, and management does not expect the adoption to have a material impact on results of operations, financial position, or cash flows. - A second FASB standard affecting internal-use software accounting is also effective for that annual cycle, with the Company describing the guidance as neutral to different software development methods; the filing evidence does not call out any other pending accounting policy shifts.

- Management commentary on the Invigorate multi-year program emphasizes savings and productivity improvements intended to partially offset pressures from the current inflationary environment, including labor and benefit cost increases and reimbursement pressures, and notes the use of automation and artificial intelligence across the value chain. - Restructuring charges incurred during the three-month reporting period were recorded in both cost of services and selling, general and administrative expenses, and restructuring charges incurred during the six-month year-to-date period were likewise recorded across cost of services and selling, general and administrative expenses, indicating ongoing Invigorate-related activity in the period.

- The Company's Diagnostic Solutions group is described as the residual grouping that captures risk assessment services for insurers and healthcare information technology businesses serving healthcare providers and payers, providing context for the composition of consolidated net revenues. - The filing evidence does not attribute this change to any single cause. - Management does not provide forward guidance in the cited narrative; readers looking for an outlook should rely on the MD&A discussion under Item 2 and on the risk discussion under Item 3, while noting that the filing evidence offers no peer or industry benchmark for sizing the move.

- The filing evidence contains no peer or industry comparison.

Operating drivers and segments

- Reported revenue moved higher year-over-year on both reporting windows, consistent with the profit-to-profit transition shown in the Broadcom Posts Higher Revenue, Operating Income, and Diluted EPS Year-Over-Year in Filing pattern, with $5,938,000,000 exceeding $5,413,000,000 for the six months ended June 30, 2026 versus the six months ended June 30, 2025 and $3,043,000,000 exceeding $2,761,000,000 for the three months ended June 30, 2026 versus the three months ended June 30, 2025. - Operating income moved higher year-over-year on both windows as well, with $858,000,000 exceeding $784,000,000 for the half-year view and $459,000,000 exceeding $438,000,000 for the quarter view, preserving a profit-to-profit transition in both periods. - The narrative distinguishes two customer groupings: the diagnostic information services, or DIS, channel covering physicians, hospitals, and patients and consumers; and the Diagnostic Solutions, or DS, group covering risk assessment services and healthcare information technology offerings, with DS described as the balance of consolidated net revenues not captured within DIS. - No segment-level revenue, contribution margin, or organic-versus-acquired split is disclosed in the narrative, so any comparison of DIS versus DS growth, mix shift, or profitability leverage between the periods must remain qualitative and unsupported.

- Management frames QUEST DIAGNOSTICS INC as operating across the healthcare ecosystem through diagnostic information services, describing the diagnostic insights derived from its clinical lab database as the mechanism by which physicians, hospitals, and patients are meant to take action to improve health outcomes. - Management identifies its primary customer channels as physicians (including accountable care organizations and Federally Qualified Health Centers), hospitals, and patients and consumers, with health plans, employers, retail healthcare providers, government agencies, pharmaceutical companies, and other commercial clinical laboratories listed as other customer categories. - Management attributes the breadth of access to a network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources such as call centers, mobile phlebotomists, nurses, and other health and wellness professionals. - Management cites an in-house medical and scientific staff — medical directors, scientific directors, genetic counselors, and board-certified geneticists — as supporting medical and scientific consultation regarding tests and test results. - Management explains that operating results for the interim periods are not necessarily indicative of results that may be expected for the full year, and that the interim statements rely on estimates and assumptions affecting reported assets, liabilities, revenues, and expenses. - Management notes that, in September, the FASB issued a new accounting standard impacting internal-use software accounting by removing references to software development project stages, with the cross-reference appearing within the discussion tied to controls and procedures under Item 4. - Management states that accounting policies follow those set forth in Note 2, the referenced note to the audited consolidated financial statements contained in the Company's prior Annual Report on Form.

(omitted) directional context between reported figures and the management framing cannot be linked causally. The filing evidence does not attribute this change to any single cause. The filing evidence contains no peer or industry comparison.

Cash flow and capital

Reported facts

- Cash and cash equivalents stood at $626,000,000 USD as of the balance sheet date of June 30, 2026, per the balance sheet within the 10-Q filed under accession 0001022079-26-000070 for QUEST DIAGNOSTICS INC (DGX, CIK 0001022079, period period-ended-2026-06-30). - Long-term debt, excluding current maturities, was $5,632,000,000 USD on the same balance-sheet date, the company's main non-current borrowing stack. - For the six-month year-to-date period, operating cash flow was $875,000,000 USD, compared with $858,000,000 USD in the prior-year window. - Investing activities used -$286,000,000 USD in the current six-month period versus -$239,000,000 USD a year earlier. - Financing activities used -$381,000,000 USD over the same six-month period, against -$854,000,000 USD in the prior-year comparable. - Capital expenditures (payments to acquire property, plant, and equipment) totaled $252,000,000 USD for the current six months and $225,000,000 USD for the prior-year period. - Cash returned to shareholders combined ordinary dividends of $184,000,000 USD with share repurchases of $102,000,000 USD, against $174,000,000 USD of dividends and $0 USD of repurchases in the year-ago window.

Management explanations - The liquidity and capital-resources discussion in Item 2 frames the company's automation and productivity program, with restructuring and impairment activity flowing through cost of services, selling, general and administrative expenses, and other operating expense (income), net, primarily in the DIS business. - The notes describe a new Michigan laboratory venture with Corewell Health, including contributed intangibles being amortized over the cited useful life and goodwill allocated to the DIS segment, as detailed in the business-acquisition discussion that cross-references Note 6.

Analyst inference - Operating cash flow was positive in both windows and moved higher in the current six-month period than in the prior-year comparable — consistent with the same direction as reported profit growth and supportive of internal funding for both capex and shareholder returns. - Investing cash outflows widened year over year in the current six-month window, consistent with elevated property, plant, and equipment outlays and incremental acquisition-related spending tied to the Michigan transaction described above. - Financing outflows also widened, consistent with larger share-repurchase and dividend cash outflows alongside balance-sheet activity — repurchases went from effectively flat in the prior-year period to positive cash use in the current period. - The combination of higher operating cash generation and higher investing and financing outflows leaves cash and cash equivalents at $626,000,000 USD alongside $5,632,000,000 USD of non-current borrowings, reflecting the trade-off between growth investment and capital return.

Counter-evidence and unknowns - The filing evidence does not attribute this change to any single cause. for any single driver of the operating, investing or financing cash flow changes versus the prior-year period. - The balance-sheet disclosure does not break out current maturities of long-term debt, lease liabilities, or pension obligations here, so the consolidated leverage picture is necessarily incomplete on this page. - The filing evidence contains no peer or industry comparison., leaving any read on whether the buyback pace and dividend ramp are aggressive or conservative versus sector norms to the reader's own benchmarking. - The filing evidence does not disclose segment-level detail for this dimension. for cash-flow detail by reportable segment; the narrative ties restructuring and acquisition activity to the DIS business, but the cash-flow statement itself is presented on a consolidated basis only.

Peer and historical context

- Readers evaluating QUEST DIAGNOSTICS INC (DGX) on a year-over-year basis can frame the quarter-to-quarter prior-period movement using the filings for two other healthcare-adjacent issuers already in the public record, such as Broadcom Posts Higher Revenue, Operating Income, and Diluted EPS Year-Over-Year in Filing and REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing, which also moved in the same direction across the comparable headline metrics. - The fact that QUEST DIAGNOSTICS INC reported a profit in the three-month period and that the comparative for the prior-year three-month period was also a profit — with the authorized transition reading profit to profit — is consistent with the pattern visible in those cross-sector examples, although the companies are not direct competitors and the size of the move cannot be inferred from the cited filings. - For longer-dated triangulation, prior Lizely Finance interim analyses such as Lizely Finance Earnings Analysis — ANI Pharmaceuticals Interim Filing: Profit-to-Profit Growth on Both Windows and Lizely Finance Earnings Analysis — UFP TECHNOLOGIES INC Interim Filing: Profit-to-Profit Growth on Both Windows document the same profit-to-profit transition on both the three-month and six-month windows, again without establishing a clean like-for-like peer set. - The strongest counterpoint to drawing a clean peer read-across is that none of the cited comparables operate in clinical laboratory diagnostics, so the direction of movement may match while the underlying mix, scale, and reimbursement exposure are structurally different; readers should treat the parallelism as a directional observation rather than a benchmark. - A further limitation is that the filing evidence for 10-Q for period-ended-2026-06-30 does not publish segment-to-segment detail, no industry table is reproduced, and no rival's filing is referenced inside the document itself. - Cross-reference to Item 2 ("Management's Discussion and Analysis of Financial Condition and Results of Operations") and to Note 6 (the business combinations note) confirms the disclosures are framed around the registrant's own results and the recently closed Michigan laboratory transaction rather than against a named competitor, which tempers any peer-based conclusion. <prose> Year-over-year, every authorized metric in the 10-Q filed under accession 0001022079-26-000070 for QUEST DIAGNOSTICS INC (CIK 0001022079) for period-ended-2026-06-30 moved in the same direction against the prior-year comparative on both the three-month and six-month windows. Revenue from Contract with Customer, Excluding Assessed Tax was higher than the prior period in both the quarter the three months ended June 30, 2026 versus the three months ended June 30, 2025 and the half-year the six months ended June 30, 2026 versus the six months ended June 30, 2025. Operating Income (Loss) was higher than the prior period on both windows, and Net Income (Loss) Attributable to Parent was higher than the prior period on both windows, with each period also representing a profit, yielding an authorized transition of profit to profit on the income statement lines. Net Cash Provided by (Used in) Operating Activities was higher than the prior-year half-year comparative, indicating the operational improvement also showed up in cash generation rather than being a paper movement.

Against the company's own history, the half-year numbers therefore tell a broadly consistent story with the quarter, with no divergence between the two reporting windows — a feature readers can confirm by looking at the two adjacent columns in the consolidated statements of operations referenced through Item 2. the filing does not, however, restate multi-year history or provide a five-year selected-financial-data table inside the interim document, so any longer historical trend reading has to lean on prior Lizely Finance coverage of comparable issuers rather than on the registrant's own longer-dated table.

On the peer dimension, the document itself does not name a competitor, publish market-share data, or include an industry comparison set. Readers seeking a directional sanity check can triangulate against filings on other healthcare and healthcare-adjacent issuers already covered by Lizely Finance, including the Broadcom and Reinsurance Group of America quarterly write-ups and the two prior profit-to-profit interim analyses cited above; the direction of movement aligns, but the magnitudes are not directly comparable because those issuers operate in different sub-sectors. The Michigan laboratory combination with Corewell Health, discussed in Note 6, is the only structural change called out in the source narrative and is too recent and immaterial in pro-forma terms to function as a peer benchmark on its own.

Scenario analysis

- Reported facts: Revenue from Contract with Customer, Excluding Assessed Tax for the three-month reporting period was $3,043,000,000 USD versus $2,761,000,000 USD in the prior-year comparative window; for the six-month year-to-date period it was $5,938,000,000 USD versus $5,413,000,000 USD. Net Income (Loss) Attributable to Parent for the quarter was $320,000,000 USD against $282,000,000 USD, and for the half-year window was $572,000,000 USD against $502,000,000 USD. - Management explanations: The cited note Note 12 discusses supplemental pro forma combined financial information alongside the Haystack contingent consideration obligation; Note 7 and Note 6 supplement the audited consolidated financial statements contained in the Company's Annual Report. - Analyst inference: Both windows exhibit authorized profit-to-profit growth on the top line and on net income, consistent with a stable baseline in which reported momentum continues without a structural shift. - Counter-evidence: The filing evidence does not attribute this change to any single cause. - Unknowns: The filing evidence contains no peer or industry comparison. and The filing evidence does not disclose segment-level detail for this dimension.

- Reported facts: A stronger-than-baseline read requires the same authorized increases to extend for both windows. Revenue from Contract with Customer, Excluding Assessed Tax was $3,043,000,000 USD for the three months ended June 30, 2026 versus $2,761,000,000 USD for the three months ended June 30, 2025, and was $5,938,000,000 USD for the six months ended June 30, 2026 versus $5,413,000,000 USD for the six months ended June 30, 2025. Net Income (Loss) Attributable to Parent was $320,000,000 USD versus $282,000,000 USD, and $572,000,000 USD versus $502,000,000 USD. - Management explanations: The Haystack contingent consideration obligation includes revenue-based benchmarks referenced in the cited note, and the CMS-reimbursement milestone remains open. - Analyst inference: If those revenue benchmarks and the CMS milestone are achieved, the contingent payout could lift reported net income without a corresponding top-line change, an asymmetric tail not captured in the headline authorization. - Counter-evidence: Reimbursement coverage from the Centers for Medicare and Medicaid Services is a future event; the fair-value model for that leg is principally management's estimate, per the cited note. - Unknowns: The filing evidence does not attribute this change to any single cause.

- Reported facts: A weaker read would interrupt the authorized increase on at least one window. Revenue from Contract with Customer, Excluding Assessed Tax was $3,043,000,000 USD for the three months ended June 30, 2026 versus $2,761,000,000 USD, with the half-year at $5,938,000,000 USD versus $5,413,000,000 USD; Net Income (Loss) Attributable to Parent was $320,000,000 USD versus $282,000,000 USD and $572,000,000 USD versus $502,000,000 USD. - Management explanations: Trading securities tied to the deferred compensation plan sit in Level 1 of the fair value hierarchy and revalue each period through other comprehensive items, which can mask operating momentum. - Analyst inference: A scenario in which top-line authorization softens while mark-to-market noise from the Level 2 fair-value tier persists would compress the visible margin path even if reported net income remained a profit. - Counter-evidence: The filing evidence does not attribute this change to any single cause. - Unknowns: The filing evidence contains no peer or industry comparison.

For a cross-issuer sanity check on revenue-plus-net-income growth, see REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in period-ended-2026-06-30 Filing.

Risks and what to watch

- Reported facts from 10-Q filed by QUEST DIAGNOSTICS INC for period-ended-2026-06-30 show Revenue from Contract with Customer, Excluding Assessed Tax of $3,043,000,000 for the three months ended June 30, 2026 and $5,938,000,000 for the six months ended June 30, 2026, with the prior-period comparatives at $2,761,000,000 for the three months ended June 30, 2025 and $5,413,000,000 for the six months ended June 30, 2025. Net Income (Loss) Attributable to Parent printed at $320,000,000 for the three months ended June 30, 2026 and $572,000,000 for the six months ended June 30, 2026, against $282,000,000 for the three months ended June 30, 2025 and $502,000,000 for the six months ended June 30, 2025.

The authorized year-over-year comparisons for both top-line and bottom-line line items point higher on both the three-month and six-month windows, with profits remaining profits in every window. - Management explanations surface two structural risk pockets. The first is the Haystack contingent consideration obligation tied to revenue benchmarks through a stated horizon and to a separate CMS reimbursement milestone; both slices are classified within Level 3 of the fair value hierarchy because the fair values depend on significant inputs that are not observable, with an additional market discount rate overlay noted in the cited note.

The second is the equity investment portfolio concentrated in life sciences and healthcare holdings, whose fair values move with quoted market prices and remain exposed to single-industry sentiment shocks. The deferred compensation obligation and its associated cash surrender value are classified within Level 2 of the fair value hierarchy, which is a softer exposure than the Level Three items but still tied to observable-but-correlated market data. - Analyst inference flags the asymmetry between the strict observable market exposures and the unobservable Level Three exposures.

The Haystack earn-out can swing the income statement even if the underlying diagnostics franchise performs within expectations, because the Monte Carlo valuation for the revenue benchmark slice and management's estimate for the CMS slice both rely on inputs that cannot be sourced from active markets. Investors should treat the next reimbursement-coverage determination and any update to the comparable-company revenue volatility assumption as discrete catalysts rather than background noise. - Counter-evidence to a smooth read-through is thin within the window.

The filing notes that the fair value of the contingent consideration obligation is not overly sensitive to movements in the comparable company revenue volatility or the discount rate for the benchmark-dependent portion, which softens the Level Three risk for that slice. Management's own commentary in Item 2 frames the disclosures in market-risk terms, and Item 4 confirms the controls and procedures posture that underpins the reported figures, while Item 3 points readers to the broader market-risk discussion. The filing evidence does not attribute this change to any single cause.

- Unknowns include the segment-level mix that drives the revenue outperformance, the pacing of any further Haystack-style contingent payouts, and the magnitude of mark-to-market swings from the equity portfolio between reporting dates. The filing evidence does not disclose segment-level detail for this dimension. The filing evidence contains no peer or industry comparison.

- Metrics to watch next period are the Haystack revenue benchmark trajectory and any CMS coverage determination that could shift the Level Three fair value, the mark-to-market move on the life sciences equity portfolio sitting in Level 1, and the continuity of the profit-to-profit transitions on both revenue and net income. For cross-issuer context, see Broadcom Posts Higher Revenue, Operating Income, and Diluted EPS Year-Over-Year in Filing and REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing.